Recent findings show that female cancer survivors receiving screening mammography display “worse health behaviors” than women receiving mammography screening who have never had cancer.
The study, conducted by researchers at Moffitt Cancer Center in Tampa, FL, and the Mayo Clinic in Rochester, MN, was published in a recent issue of the American Journal of Clinical Oncology.
The first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy has been approved by the FDA.
Anticipating future events may contribute to stress-related increased risk for the diseases of aging, including cancer, according to a study to be published in the May issue of the journal Brain, Behavior and Immunity.
Many women endure hot flashes and night sweats following breast cancer treatment. British researchers are now saying that cognitive behavioral therapy (CBT) is an effective treatment for women experiencing these main symptoms of menopause.
A warning has been issued by the FDA regarding a counterfeit version of Avastin 400 mg/16 mL, which may have been purchased and utilized by medical practices in the United States. Chemical analyses of the imitation vials have confirmed the product lacks the active ingredient of Avastin, bevacizumab, which may have resulted in patients not receiving needed therapy.
Packages or vials may be counterfeit if:
A newly patented computerized system effectively chooses the right patient for the right clinical trial. The program quickly matches a registered patient’s molecular profile to a disease-targeting drug’s molecular design. According to the Moffit Cancer Center, the system will accelerate clinical trials and help reduce the time required for critical new drugs to reach the market.
For the first time, the effect of exemestane on women’s bone health has been studied, and researchers found that, on 3 major outcome measures, age-related bone loss in postmenopausal women taking exemestane for 2 years worsened.
“The study is important because of the potential for wide-spread use of this medication by women at increased risk of developing breast cancer,” said Dr Lianne Tile, Medical Director of the Osteoporosis Clinic and Staff General Internist at University Health Network, and one of the authors of the study.
Cachexia affects many patients with advanced cancer. It causes excessive weight loss, severe fatigue, and diminishes quality of life. Now, new research has found that patients with severe cancer-related fatigue also have less muscle mass and strength compared with patients who are less impaired.
“Ours is the first study to identify the relationship between chronic fatigue and muscle mass and strength in this special patient population,” says first author Robert Kilgour, professor and chair of Concordia University’s Department of Exercise Science.
The use of low molecular weight heparin (LMWH), an injectable, clot-preventing drug for patients with advanced cancer, increased steadily between 2000 and 2007, according to a new study published in The Oncologist. However, use of LMWH is low compared with another anticoagulant, warfarin, despite previous research demonstrating LMWH as the preferred treatment for patients with cancer suffering blood clots.
As a result of federal legislation, electronic health records (EHRs) are becoming an integral part of nurses’ daily practice. Now, a large study has determined the multiple benefits of implementing EHRs in the medical setting.
A study published in the Journal of Nursing Administration involved more than 16,000 nurses working at 316 hospitals in 4 states. Researchers found more improvements to nursing care and better health outcomes for patients when EHRs were in use.
To sign up for our newsletter or print publications, please enter your contact information below.
